The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. P...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pharmacogenomics J
Main Authors: Feng, QiPing, Wei, Wei-Qi, Chung, Cecilia P, Levinson, Rebecca T, Bastarache, Lisa, Denny, Joshua C., Stein, C Michael
Format: Artigo
Sprog:Inglês
Udgivet: 2016
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4995153/
https://ncbi.nlm.nih.gov/pubmed/26902539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2016.3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker